[go: up one dir, main page]

SE0402221D0 - Treatment of insufficient perfusion - Google Patents

Treatment of insufficient perfusion

Info

Publication number
SE0402221D0
SE0402221D0 SE0402221A SE0402221A SE0402221D0 SE 0402221 D0 SE0402221 D0 SE 0402221D0 SE 0402221 A SE0402221 A SE 0402221A SE 0402221 A SE0402221 A SE 0402221A SE 0402221 D0 SE0402221 D0 SE 0402221D0
Authority
SE
Sweden
Prior art keywords
treatment
insufficient perfusion
composition
perfusion
insufficient
Prior art date
Application number
SE0402221A
Other languages
English (en)
Swedish (sv)
Original Assignee
Aerocrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerocrine Ab filed Critical Aerocrine Ab
Priority to SE0402221A priority Critical patent/SE0402221D0/xx
Publication of SE0402221D0 publication Critical patent/SE0402221D0/xx
Priority to EP05783432A priority patent/EP1789060A1/fr
Priority to US10/573,335 priority patent/US8552068B2/en
Priority to PCT/SE2005/001336 priority patent/WO2006031191A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0402221A 2004-09-14 2004-09-14 Treatment of insufficient perfusion SE0402221D0 (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE0402221A SE0402221D0 (sv) 2004-09-14 2004-09-14 Treatment of insufficient perfusion
EP05783432A EP1789060A1 (fr) 2004-09-14 2005-09-14 Compositions comprenant des composes capables de former une liaison reversible ou une association avec l'oxyde nitrique gazeux
US10/573,335 US8552068B2 (en) 2004-09-14 2005-09-14 Compositions and methods
PCT/SE2005/001336 WO2006031191A1 (fr) 2004-09-14 2005-09-14 Compositions comprenant des composes capables de former une liaison reversible ou une association avec l'oxyde nitrique gazeux

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0402221A SE0402221D0 (sv) 2004-09-14 2004-09-14 Treatment of insufficient perfusion

Publications (1)

Publication Number Publication Date
SE0402221D0 true SE0402221D0 (sv) 2004-09-14

Family

ID=33157545

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0402221A SE0402221D0 (sv) 2004-09-14 2004-09-14 Treatment of insufficient perfusion

Country Status (4)

Country Link
US (1) US8552068B2 (fr)
EP (1) EP1789060A1 (fr)
SE (1) SE0402221D0 (fr)
WO (1) WO2006031191A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613856D0 (en) * 2006-07-13 2006-08-23 Isis Innovation Method for reducing spasms
US20080146579A1 (en) * 2006-12-15 2008-06-19 N.V. Nutricia Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore
CN101835502A (zh) 2007-09-21 2010-09-15 伊诺克斯生物制药公司 释放抗微生物气体的耳引流管
EP2707103A2 (fr) * 2011-05-09 2014-03-19 Topical Therapeutic Agent (TTA) Ltd. Formulations topiques capturant l'oxyde nitrique
US10557234B2 (en) 2012-05-29 2020-02-11 Neozyme International, Inc. Papermaking additive compositions and methods and uses thereof
US10334856B2 (en) 2012-05-29 2019-07-02 Neozyme International, Inc. Non-toxic pest control compositions and methods and uses thereof
BR112014030063B1 (pt) 2012-05-29 2021-04-06 Neozyme International, Inc. composição biocatalítica e processo para o tratamento biológico de um material orgânico
US10681914B2 (en) 2012-05-29 2020-06-16 Neozyme International, Inc. Non-toxic plant agent compositions and methods and uses thereof
US11193077B1 (en) 2013-03-13 2021-12-07 Airworthy Autogas, Llc Gasoline for aircraft use
GB2579240B (en) 2018-11-27 2020-12-16 Attgeno Ab New processes, compositions and medical uses
CA3177023A1 (fr) 2020-04-26 2021-11-04 Neozyme International, Inc. Compositions en poudre seche et procedes et utilisations de celles-ci
EP4142896A4 (fr) 2020-04-26 2024-06-12 Neozyme Inernational, Inc. Compositions d'extinction d'incendie non toxiques, dispositifs et procédés d'utilisation de ceux-ci
GB202007929D0 (en) 2020-05-27 2020-07-08 Attgeno Ab New medical uses
GB202306258D0 (en) 2023-04-27 2023-06-14 Attgeno Ab New medical uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9102812L (sv) 1991-09-27 1993-01-18 Lars Erik Gustafsson Saett att faststaella aktuell lungfunktion samt anordning foer att indikera naemnda lungfunktion
EP1023900B1 (fr) 1991-11-14 2005-03-16 The Brigham And Women's Hospital, Inc. Composition pharmaceutique contenant S-nitroso-lipoproteines et son utilisation
US5646181A (en) * 1992-07-02 1997-07-08 Research Foundation Of State University Of New York Method and compositions for treating impotence
WO1994016740A1 (fr) 1993-01-29 1994-08-04 Brigham And Women's Hospital Utilisation de composes d'apport d'oxyde nitrique pour le traitement ou la prevention des problemes dus a une cirrhose alcoolique du foie
AU6523194A (en) 1993-03-26 1994-10-24 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
WO1995002181A1 (fr) 1993-07-06 1995-01-19 Kjell Alving Systeme permettant de determiner les niveaux de no dans l'air expire et methodes de diagnostic des troubles lies a des niveaux de no anormaux
US6087479A (en) * 1993-09-17 2000-07-11 Nitromed, Inc. Localized use of nitric oxide-adducts to prevent internal tissue damage
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
JPH11513703A (ja) 1995-10-20 1999-11-24 レール・リキード・ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード 医薬として用いられる一酸化窒素に基づく組成物
US6294517B1 (en) * 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US20020061879A1 (en) * 1996-02-02 2002-05-23 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
DE19654895C2 (de) 1996-02-07 2000-07-27 Sanol Arznei Schwarz Gmbh Detektionsverfahren
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6589759B1 (en) 1999-03-30 2003-07-08 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
US6737447B1 (en) * 1999-10-08 2004-05-18 The University Of Akron Nitric oxide-modified linear poly(ethylenimine) fibers and uses thereof
DE60131644T2 (de) * 2000-05-09 2008-10-30 Nitromed, Inc., Lexington Infrarotthermographie und behandlung von sexuellen dysfunktionen
AU2001264729A1 (en) * 2000-05-22 2001-12-03 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
US6706274B2 (en) * 2001-01-18 2004-03-16 Scimed Life Systems, Inc. Differential delivery of nitric oxide
US6673338B1 (en) * 2001-09-10 2004-01-06 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same
AU2003270689A1 (en) 2002-09-19 2004-04-08 New York University Control of nitric oxide bioactivity by perfluorocarbons

Also Published As

Publication number Publication date
WO2006031191A1 (fr) 2006-03-23
WO2006031191A8 (fr) 2006-12-28
EP1789060A1 (fr) 2007-05-30
US20080293813A1 (en) 2008-11-27
US8552068B2 (en) 2013-10-08

Similar Documents

Publication Publication Date Title
SE0402221D0 (sv) Treatment of insufficient perfusion
WO2013061083A3 (fr) Agents thérapeutiques et utilisations de ceux-ci
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
UY27720A1 (es) Aroilpiridinonas monocíclicas,
TW200531702A (en) Pharmaceutical preparation comprising an antibody against the egf receptor
MX2010010954A (es) Farmaco contra cancer de higado.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
AR063604A1 (es) Atenuacion de la vasoconstriccion inducida por un portador de oxigeno vasoactivo
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
MX2007000979A (es) Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada.
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
TW200626558A (en) Indazolone derivatives
NZ625440A (en) Anti-cxcr1 compositions and methods
WO2008048514A3 (fr) Oxyde nitrique topique en tant que traitement de maladies auto-immunes
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
MXPA05010402A (es) Oxido nitrico en el tratamiento de la inflamacion.
EP4488289A3 (fr) Facteurs de coagulation à action prolongée et leurs utilisations
NZ578065A (en) Methods for treating psoriasis with an antibody which binds to an epitope
WO2009099998A3 (fr) Traitement thérapeutique de conditions pulmonaires
SG196863A1 (en) Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
TW200800954A (en) Novel crystal modifications
MX377688B (es) Métodos para administrar óxido nítrico a la sangre arterial o arterializada.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
GB2432314B (en) Topical medicament comprising menthol, camphor, potassium and a source of oxygen